

**I. AMENDMENTS TO THE CLAIMS**

This listing of claims shall replace all prior version, and listings, of claims in the application.

**Listing of Claims**

1-37. (cancelled)

38. (currently amended): A method of effectively treating pain in humans, ~~comprising~~ consisting of orally administering to a human patient an oral dosage form consisting essentially of (i) nabumetone or at least one pharmaceutically acceptable salt thereof; (ii) oxycodone or at least one pharmaceutically acceptable salt thereof; and (iii) at least one pharmaceutically acceptable excipient.

39-46. (cancelled)

47. (currently amended): The method of claim 38, wherein the weight ratio of the oxycodone ~~or at least one pharmaceutically acceptable salt thereof~~ to the nabumetone ~~or at least one pharmaceutically acceptable salt thereof~~ is from about 0.0001:1 to about 1:1.

48. (previously presented): The method of claim 38, wherein the oxycodone is present in the pharmaceutically acceptable salt form.

49. (currently amended): The method of claim 38, wherein the at least one pharmaceutically acceptable excipient is a sustained release carrier which provides a sustained release of the oxycodone ~~or at least one pharmaceutically acceptable salt thereof~~.

50. (currently amended): The method of claim 38, wherein the at least one pharmaceutically acceptable excipient provides a sustained release of the nabumetone ~~or~~

~~at least one pharmaceutically acceptable salt thereof;~~ and the oxycodone ~~or at least one pharmaceutically acceptable salt thereof.~~

51. (currently amended): The method of claim 38, wherein the nabumetone ~~or at least one pharmaceutically acceptable salt thereof~~ is present in an amount from about 0.5 mg to about 1500 mg.

52. (currently amended): The method of any one of claims 38, 47, 49, 50 or 51, wherein an amount of the oxycodone in the dosage form is from 2.5 mg to 800 mg.

53. (currently amended): A method of effectively treating pain in humans, comprising orally administering to a human patient an oral dosage form consisting essentially of (i) nabumetone or at least one pharmaceutically acceptable salt thereof in an immediate release form; (ii) oxycodone or at least one pharmaceutically acceptable salt thereof in a sustained release form; and (iii) and at least one pharmaceutically acceptable excipient.

54. (previously presented): The method of claim 53, wherein the sustained release form consists essentially of the oxycodone in an amount of about 2.5 mg to 800 mg and a sustained release carrier in an amount such that said oral dosage form provides a therapeutic effect of the oxycodone for at least 12 hours or longer.

55. (previously presented): The method of claim 54, wherein said sustained release carrier is selected from the group consisting of an alkylcellulose; a hydroxyalkylcellulose; an acrylic polymer; a fatty acid; a fatty alcohol; a glyceryl ester of fatty acids; a mineral oil or wax; a vegetable oil or wax; a polyalkylene glycol; shellac; zein; and mixtures of any of the foregoing.

56. (currently amended): The method of claim 53, wherein said pain is selected from the group consisting of cancer pain, post-surgical pain, low back and neck pain, dysmenorrheal, headache, toothache, and pain from sprains and strains, myositis, neuralgia, synovitis, arthritis, degenerative joint diseases, gout and ankylosing

spondylitis, bursitis, burns, injuries, influenza or other viral infections, ~~and~~ or common cold.

57. (previously presented): The method of claim 53, wherein said dosage form is in a form of particles having a diameter from about 0.1 mm to about 2.5 mm.

58. (previously presented): The method of claim 57, wherein said particles have diameter from about 0.5 mm to about 2 mm.

59. (previously presented): The method of claim 53, wherein the nabumetone is coated onto a tablet comprising the oxycodone in the sustained release form.

60. (currently amended): The method of claim 54, wherein said sustained release carrier is being (i) a sustained release coating; or (ii) incorporated into a matrix with said oxycodone.

61. (previously presented): The method of claim 53, wherein said oral dosage form provides a therapeutic effect of said oxycodone for about 24 hours.

62. (currently amended): A method of effectively treating pain in humans, ~~comprising~~ consisting of orally administering to a human patient an oral dosage form consisting essentially of (i) nabumetone and at least one pharmaceutically acceptable salt thereof; (ii) oxycodone and at least one pharmaceutically acceptable salt thereof; and (iii) at least one pharmaceutically acceptable excipient.

63. (currently amended): The method of claim 62, wherein the weight ratio of the oxycodone and the at least one pharmaceutically acceptable salt thereof to the nabumetone and the at least one pharmaceutically acceptable salt thereof is from about 0.0001:1 to about 1:1.

64. (currently amended): The method of claim 62, wherein the at least one pharmaceutically acceptable excipient is a sustained release carrier which provides a sustained release of the oxycodone and the at least one pharmaceutically acceptable salt thereof.

65. (currently amended): The method of claim 62, wherein the at least one pharmaceutically acceptable excipient provides a sustained release of the nabumetone and the at least one pharmaceutically acceptable salt thereof.

66. (currently amended): The method of claim 38, wherein the nabumetone ~~or at least one pharmaceutically acceptable salt thereof~~ is present in an amount of 1000 mg.

67. (currently amended): The method of claim 53, wherein the nabumetone ~~or at least one pharmaceutically acceptable salt thereof~~ is present in an amount of 1000 mg.

68. (currently amended): The method of claim 38, wherein from 25 mg to 300 mg of the nabumetone is administered.

69. (currently amended): The method of claim 68, wherein 100 mg of the nabumetone is administered.

70. (currently amended): The method of claim 53, wherein from 25 mg to 300 mg of the nabumetone is administered.

71. (currently amended): The method of claim 70, wherein 100 mg of the nabumetone is administered.

72. (currently amended): The method of claim 62, wherein from 25 mg to 300 mg of the nabumetone is administered.

Appl. Serial No. 10/056,348  
Response dated February 28, 2011  
Reply to Office Action dated August 26, 2010

73. (currently amended): The method of claim 72, wherein 100 mg of the nabumetone is administered.